Navigation Links
Rigel to Host Conference Call to Discuss Results of Its Phase 2b TASKi2 Clinical Trial of R788 in Rheumatoid Arthritis
Date:7/8/2009

SOUTH SAN FRANCISCO, Calif., July 8 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that the Company plans to host a conference call on Thursday, July 9, 2009 at 8:00 am EDT (5:00 am PDT). Members of Rigel's senior management team and the principal investigator of the trial will discuss results of the Company's Phase 2b TASKi2 clinical trial of R788 in rheumatoid arthritis, the Company's plans for further development and related matters.

Conference Call and Webcast Information

To access the live call, please dial 866-543-6408 (domestic) or 617-213-8899 (international) 10 minutes prior to the start time and use the passcode 40038100. A replay of the call will be available at approximately 11:30 a.m. EDT on July 9, 2009 until July 16, 2009. To access the replay, please dial 888-286-8010 (domestic) or 617-801-6888 (international) and use the passcode 48864759. The conference call will also be webcast live and can be accessed from Rigel's website at http://www.rigel.com. Please connect to Rigel's website several minutes prior to the start of the live webcast to ensure adequate time for any software downloads that may be necessary.

About Rigel (www.rigel.com)

Rigel is a clinical-stage drug development company that discovers and develops novel, small molecule drugs for the treatment of inflammatory/autoimmune diseases and metabolic diseases. Our pioneering research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. Rigel's productivity has resulted in strategic collaborations with large pharmaceutical partners to develop and market our product candidates. Rigel has product development programs in inflammatory/autoimmune
'/>"/>

SOURCE Rigel Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Rigel Announces Initiation of Phase 1 Clinical Trial of R343 for Allergic Asthma by its Partner Pfizer
2. Rigels R788 Demonstrates Significant Improvement in Rheumatoid Arthritis in Phase 2 Clinical Study
3. Rigel Announces Initiation of Phase 1 Clinical Trial of R348 for Rheumatoid Arthritis, Psoriasis and Other Immune Disorders
4. Rigels R788 Shows Preclinical Activity in Type 1 Diabetes Model
5. Rigels R788 Slows Progression of Murine Lupus in Preclinical Studies
6. Rigel to Host Conference Call to Discuss Preliminary Phase 2 Study Results of R788 in Lymphoma
7. Rigels R788 Phase 2a Results Published in Arthritis and Rheumatism
8. Rigel Expects R788 Partnership After Phase 2b Clinical Trials Results
9. Shareholder Class Action Filed Against Rigel Pharmaceuticals, Inc. by the Law Firm of Barroway Topaz Kessler Meltzer & Check, LLP
10. Rigel Commences Phase 2 Trial of R788 in Peripheral T-Cell Lymphomas
11. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... Pa. , July 31, 2015 ... fully integrated specialty pharmaceutical company focused on developing, ... the closing of its previously announced underwritten public ... at a public offering price of $11.25 per ... offering included 1,000,000 shares issued upon the exercise ...
(Date:7/31/2015)... According to a new market ... Analyzers (BIA), Dual-Energy X-ray Absorptiometry (DEXA), Skinfold Calipers, Air ... & Forecast to 2019", published by MarketsandMarkets, the global ... 2014 and is estimated to grow to $1,425.7 Million ... 2014 to 2019. Browse 41 market ...
(Date:7/30/2015)... July 30, 2015  ResMed (NYSE: ... a definitive agreement to acquire Curative Medical, ... and sleep-disordered breathing medical devices and accessories. ... in China, combined with ResMed,s global leadership in sleep and respiratory ... China suffering from sleep-disordered ...
Breaking Medicine Technology:Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 2Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 3Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 4Body Composition Analyzers Market Worth $1,425.7 Million by 2019 2Body Composition Analyzers Market Worth $1,425.7 Million by 2019 3Body Composition Analyzers Market Worth $1,425.7 Million by 2019 4ResMed Invests in High-Growth Chinese Sleep and Respiratory Care Market with Curative Medical 2ResMed Invests in High-Growth Chinese Sleep and Respiratory Care Market with Curative Medical 3
... Cardiothoracic Surgeons to Lead Pivotal TrialANN ARBOR, Mich., March ... has appointed David Seth Feldman, MD/PhD, FACC, FAHA to ... the United States, studying the new, third generation DuraHeart(TM) ... Dr. Francis Pagani, Director of the Heart Transplant and ...
... - Conference Call Today at 5:00 p.m. Eastern Time ... Pharmaceuticals, Inc. (Nasdaq: PARD ), a biopharmaceutical ... the fourth quarter and year ended December 31, 2008, ... of 2008, we made significant progress toward our goal ...
Cached Medicine Technology:David Feldman, M.D. Appointed Co-Principal Investigator of DuraHeart(TM) Left Ventricular Assist System U.S. Clinical Trial 2David Feldman, M.D. Appointed Co-Principal Investigator of DuraHeart(TM) Left Ventricular Assist System U.S. Clinical Trial 3Poniard Pharmaceuticals Reports Fourth Quarter and Year End 2008 Financial Results and Provides a Corporate Update 2Poniard Pharmaceuticals Reports Fourth Quarter and Year End 2008 Financial Results and Provides a Corporate Update 3Poniard Pharmaceuticals Reports Fourth Quarter and Year End 2008 Financial Results and Provides a Corporate Update 4Poniard Pharmaceuticals Reports Fourth Quarter and Year End 2008 Financial Results and Provides a Corporate Update 5Poniard Pharmaceuticals Reports Fourth Quarter and Year End 2008 Financial Results and Provides a Corporate Update 6Poniard Pharmaceuticals Reports Fourth Quarter and Year End 2008 Financial Results and Provides a Corporate Update 7Poniard Pharmaceuticals Reports Fourth Quarter and Year End 2008 Financial Results and Provides a Corporate Update 8Poniard Pharmaceuticals Reports Fourth Quarter and Year End 2008 Financial Results and Provides a Corporate Update 9
(Date:8/1/2015)... ... August 01, 2015 , ... On March 19, 2015 Phil Valentine – the Executive Director of ... Appalachian Trail by stepping off Springer Mountain and heading north. Since that day, Phil ... reached Connecticut and was greeted by friends and family. He visited CCAR and left ...
(Date:7/31/2015)... ... , ... Super Bowl 50 will emanate from Levi’s Stadium in Santa Clara, CA ... the Super Bowl. In the two weeks that separate the conference championships and the Super ... Super Bowl game will mark the 50th time it has been held and the festivities ...
(Date:7/31/2015)... Tenn. (PRWEB) , ... July 31, 2015 , ... The ... Robert Church Park in Downtown Memphis on October 3, 2015. The Ride to Fight ... focused on cancer research between Methodist Healthcare, The West Clinic and The University of ...
(Date:7/31/2015)... ... ... Coco Libre announced today that their flagship Organic Coconut Water will be ... Open of Surfing, July 25 through August 2 in Huntington Beach, California. Coco Libre, ... is a natural choice given the Open’s commitment to sustainable practices. , Designated ...
(Date:7/31/2015)... ... ... Well-known for its unique pastries and delicious confections, Pastry Palace, a popular ... life just a little bit sweeter for newlyweds. A family-owned business, the Pastry Palace ... , The bakery provides a full line of custom wedding cakes. Brides can select ...
Breaking Medicine News(10 mins):Health News:Connecticut Executive Hikes Appalachian Trail to Raise Awareness About Recovery. 2Health News:Cheap 2016 Super Bowl Tickets at Levi's Stadium: Ticket Down Slashes Ticket Prices on Super Bowl 50 Tickets in Santa Clara, CA at Levi's Stadium 2Health News:West Cancer Center Announces 2nd Annual Ride to Fight On 2Health News:West Cancer Center Announces 2nd Annual Ride to Fight On 3Health News:Coco Libre Brings Eco-conscious Hydration to Vans US Open of Surfing 2Health News:Pastry Palace of Las Vegas Announces It Is Now Offering Custom Wedding Cakes in Las Vegas 2
... (NYSE: TYC , BSX: TYC) announced today that ... quarterly dividend to 15,cents per share for the first ... 36% increase over the quarterly dividend of,approximately 11 cents ... the separation of Tyco into three public companies. The,15-cent ...
... ViroPharma Incorporated,(Nasdaq: VPHM ) today announced ... financial officer of ViroPharma, will present,at the Maxim ... ET on,Thursday, September 20, 2007. The conference is ... ViroPharma,s presentation will be webcast live for ...
... straight men equally prone to unprotected sex, research shows , , ... gay men can,t be explained by their number of sexual ... HIV infections diagnosed in the United States in 2005 were ... Seattle, noted. In addition, as many as one in five ...
... Institute have shown that several, rather than just ... brain tumors and other solid tumors, explaining why ... often yields disappointing results. , The laboratory finding ... combine three or more such targeted drugs for ...
... Sept. 13 Mayo Clinic,s,Multidisciplinary Simulation Center is ... the United States to be accredited by,the American ... positions,Mayo to offer and advance medical education that ... members, abilities to keep pace with,rapidly changing technologies. ...
... Minnesota Twins and at Interlachen Country Club ... and support for suicide prevention., MINNEAPOLIS, Sept. 13 ... Prevention Week,(September 9-15, 2007) this week with a special ... at the Hubert H. Humphrey Metrodome in,Minneapolis. SAVE is ...
Cached Medicine News:Health News:Tyco International Increases Quarterly Dividend 36 Percent to 15 Cents per Share; Initiates New $1 Billion Share Repurchase Program 2Health News:Number of Partners Doesn't Explain Gay HIV Rate 2Health News:Number of Partners Doesn't Explain Gay HIV Rate 3Health News:Study suggests brain tumors need treatment with multiple 'targeted' drugs 2Health News:Study suggests brain tumors need treatment with multiple 'targeted' drugs 3Health News:Mayo Clinic Multidisciplinary Simulation Center Receives Distinction as an ACS-Accredited Education Institute 2Health News:Mayo Clinic Multidisciplinary Simulation Center Receives Distinction as an ACS-Accredited Education Institute 3Health News:SAVE Recognizes National Suicide Prevention Week 2
Microseal 'F' foil, seals plates for cold storage (or cycling >25l), disposable, pkg of 100...
Pkg qty: box of 2 bags pack of 25 (Pack = Zippered Bag)...
Transparent film for easy visual monitoring of samples...
... Biosystems has developed a comprehensive set ... using sequence detection systems (SDS) reagents ... and easy to follow. Many traditional ... and the thermal cycling protocol itself, ...
Medicine Products: